AIxCrypto Holdings, Inc. (Nasdaq: AIXC) reported a significant financial performance shift in its latest 10-K filing for the fiscal year ending December 31, 2025. The company recorded a net loss of $16.97 million, a substantial increase from the $6.26 million loss reported in the previous year. Total expenses surged to $13.20 million, up from $5.76 million in 2024, primarily driven by increased general and administrative costs, which rose from $4.20 million to $8.82 million. The company did not generate any material revenue during the year, reflecting its ongoing transition from a clinical-stage therapeutics company to a technology infrastructure provider focused on artificial intelligence and blockchain.
In a strategic realignment, AIxCrypto underwent a rebranding from Qualigen Therapeutics in November 2025 and closed a $41 million private investment in public equity (PIPE) financing. This funding was aimed at supporting its new business model centered around Real World Asset (RWA) tokenization and Embodied Artificial Intelligence (EAI) infrastructure. However, the company decided to discontinue its earlier product lines, including the BesTrade platform and C10 portfolio management tools, as they did not align with its revised focus on enterprise and institutional infrastructure.
Operationally, AIxCrypto has made notable strides, surpassing 1 million registered wallets on its AIxC Hub by early February 2026, with 200,000 daily active participants reported shortly after its launch. The company also announced a strategic partnership with BitMart to launch a co-branded virtual prepaid card, enhancing payment flexibility for digital asset users. As of December 31, 2025, AIxCrypto employed 10 individuals and engaged various consultants, including a Chief Advisor, to guide its strategic direction.
The company’s outlook remains cautious, with management acknowledging the need for additional funding to support ongoing operations and development initiatives. The filing highlighted the challenges posed by recurring losses and a working capital deficiency, raising substantial doubt about the company's ability to continue as a going concern. AIxCrypto is actively exploring options to secure further financing while navigating a rapidly evolving regulatory landscape in the digital asset and AI sectors.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics is an early-stage biotech company developing cancer treatments, focusing on small molecule therapeutics targeting genetic structures like G-quadruplexes and RAS oncogenes. Its pipeline includes QN-302 for pancreatic cancer and Pan-RAS inhibitors for multiple cancers. The company collaborates with academic institutions, advances clinical trials, and seeks regulatory approval, aiming to address unmet medical needs in oncology markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.